公开(公告)号：US09896473B2

公开(公告)日：2018-02-20

申请号：US14390747

申请日：2013-04-04

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE DE MONTPELLIER 1 ,  ETABLISSEMENT FRANÇAIS DU SANG ,  UNIVERSITE CLAUSE BERNARD LYON 1

发明人： François Morvan ,  Albert Meyer ,  Jean-Jacques Vasseur ,  Julie Mayen ,  Carole Chaix ,  Carole Farre ,  Chantal Fournier-Wirth ,  Jean-François Cantaloube ,  Myriam Lereau

IPC分类号： C07H21/04 ,  C07F9/24 ,  C07C323/52 ,  C08F257/02 ,  C12N15/11

CPC分类号： C07H21/04 ,  C07C323/52 ,  C07F9/2408 ,  C08F257/02 ,  C12N15/11

摘要： The present invention relates to a thiol compound suitable for forming a chain of oligomers that can be grafted to an oligonucleotide. The invention also relates to an oligonucleotide grafted by such a compound, thus having one or more thiol functions, suitable for being immobilized on a gold surface or on a grafted surface.

公开(公告)号：US20240158752A1

公开(公告)日：2024-05-16

申请号：US18550889

申请日：2022-03-18

申请人： ETABLISSEMENT FRANÇAIS DU SANG ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE TOULOUSE III-PAUL SABATIER ,  ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE (ENVT)

发明人： Mélanie Alexandra GADELORGE ,  Nicolas Lucien ESPAGNOLLE ,  Frédéric DESCHASEAUX

IPC分类号： C12N5/077 ,  A61P19/00 ,  C12N5/071 ,  C12N5/0775

CPC分类号： C12N5/0654 ,  A61P19/00 ,  C12N5/0653 ,  C12N5/0663 ,  C12N5/0692 ,  C12N5/0697 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/33 ,  C12N2513/00

摘要： Disclosed is a culture medium and a culture method for obtaining, in a single step and in the same culture container, cells differentiated into osteoblasts and adipocytes, as well as a network of organized endothelial cells from the same pool of mesenchymal stem cells and/or a mixture of mesenchymal stem cells, endothelial progenitor cells and endothelial cells selected beforehand and amplified simultaneously in the same culture container from a single sample. Also disclosed is a composition obtained by the method, to a bone marrow reconstitution and to uses thereof.

公开(公告)号：US20230324412A1

公开(公告)日：2023-10-12

申请号：US17995452

申请日：2021-04-08

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ETABLISSEMENT FRANÇAIS DU SANG (EFS) ,  UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE

发明人： Véronique BAUDIN-CREUZA ,  Philippe CHADEBECH ,  Corinne VASSEUR ,  France PIRENNE

IPC分类号： G01N33/72 ,  G01N33/68

CPC分类号： G01N33/721 ,  G01N33/6848

摘要： The present invention relates to a method for determining the quality of haemoglobin (Hb) during the storage period of red blood cell (RBC) units comprising a step of detecting soluble alpha-haemoglobin (α-Hb) pool in RBC lysates and concluding that the presence of α-Hb pool indicates a conservation of quality of Hb during the storage RBCs. Inventors have determined the impact of RBC units aging on the quality of Hb and on the soluble α-Hb pool level in RBCs. For this purpose, 21 RBC units were collected, stored at +4 to 6° C. and samples were taken at two different storage times (D3-D8 and D38-D42) to evaluate spectral characteristics of Hb and soluble α-Hb pool in RBCs. Two additional samples were collected from 16 RBC units, at intermediate time points during storage (D13-D17 and D24-D29; n=16). The α-Hb dosing assay uses the specific character of the interaction between the α-Hb and the AHSP, the α chaperone, to trap the α-Hb present in the RBC lysates of RBC units. They also investigated the effect of a short cryopreservation period at −80° C. for 15 days on the α-Hb pool for 4 different RBC units.

公开(公告)号：US20220398942A1

公开(公告)日：2022-12-15

申请号：US17775087

申请日：2020-11-05

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Ecole Nationale Superieure d'Arts et Metiers (ENSAM) ,  Etablissement Français du Sang ,  Assistance Publique Hôpitaux de Paris ,  Université Paris Est Creteil Val de Marne ,  Fondation Imagine

发明人： Pablo BARTOLUCCI ,  Kim-Anh NGUYEN-PEYRE ,  Christian KASSASSEYA ,  Margaux RITTER ,  Frédéric SEGONDS ,  Pierre VEDEL

IPC分类号： G09B23/30 ,  C12N5/071 ,  G06T19/20 ,  G06T7/00 ,  B29C64/124

摘要： Method for manufacturing a tridimensional blood vessel model using stereolithography and optionally cell culture. Applications include surgery training, research on pathology such as SCDs and in vitro drug testing e.g. for antiplatelets. Existing models are not compatible with cell culture and cannot withstand high pressure, as opposed to the present invention. Stereolithography allows modelling of complex vessels such as carotid siphons as opposed to other existing methods.

公开(公告)号：US11364271B2

公开(公告)日：2022-06-21

申请号：US17049221

申请日：2019-04-19

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Etablissement Français du Sang (EFS) ,  Université de Bretagne Occidentale ,  Centre Hospitalier Regional et Universitaire de Brest

发明人： Rozenn Le Berre ,  Marie-Sarah Fangous ,  Gwenaelle Le Blay ,  Geneviève Hery-Arnaud ,  Rosyne Lagrafeuille

IPC分类号： A01N63/00 ,  A61K35/747 ,  A61P31/04 ,  A61P11/00

摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.

公开(公告)号：US20210017584A1

公开(公告)日：2021-01-21

申请号：US17043100

申请日：2019-03-28

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST ,  UNIVERSITÉ DE BRETAGNE OCCIDENTALE ,  INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT ,  ETABLISSEMENT FRANÇAIS DU SANG (EFS)

发明人： Geneviève HERY-ARNAUD ,  Jérôme MOUNIER ,  Charles-Antoine GUILLOUX ,  Patricia LEPAGE ,  Stanislas MONDOT ,  Marlène KERAVEC

IPC分类号： C12Q1/689 ,  C12Q1/686

摘要： The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas catoniae compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas catoniae in a biological sample obtained from said subject.

公开(公告)号：US20190315862A1

公开(公告)日：2019-10-17

申请号：US16462754

申请日：2017-11-21

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE STRASBOURG ,  ETABLISSEMENT FRANÇAIS DU SANG (EFS)

发明人： Pierre MANGIN ,  Christian GACHET

IPC分类号： C07K16/28 ,  C12N15/115 ,  C07K14/705 ,  A61P35/04

摘要： The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.

公开(公告)号：US20160194607A1

公开(公告)日：2016-07-07

申请号：US14989310

申请日：2016-01-06

申请人： Université Pierre et Marie Curiè (Paris 6) ,  Etablissement Français du Sang ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

发明人： Luc Douay ,  Marie-Catherine Giarratana

IPC分类号： C12N5/0789

CPC分类号： C12N5/0647 ,  C12N5/0641 ,  C12N2500/25 ,  C12N2500/90 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/91

摘要： A method for the production of cells of the hematopoietic lineage includes culturing hematopoietic stem cells (HSC) or embryonic bodies with a cell culture medium (the cell culture medium includes insulin at a concentration of from 1 to 50 μg/ml, transferrin at a concentration of from 100 μg/ml to 2000 μg/ml and plasma or serum at a concentration of from 1% to 30%) under conditions allowing producing cells of the hematopoietic lineage; and collecting cells of the hematopoietic lineage.

摘要翻译： 用于制造造血谱系细胞的方法包括用细胞培养基培养造血干细胞（HSC）或胚胎体（细胞培养基包括浓度为1至50μg/ ml的胰岛素，浓度为的转铁蛋白 在100μg/ ml至2000μg/ ml的浓度范围内，血浆或血清浓度为1％至30％），在允许产生造血谱系细胞的条件下; 并收集造血谱系的细胞。